=Bellicum Pharma (BLCM) : FDA lifts the clinical hold on studies of BPX-501

Bellicum Pharma: FDA has lifted the clinical hold on studies of BPX-501 in the U.S. 
The decision follows consultation with the FDA and agreement on amendments to the study protocols including guidance on monitoring and management of neurologic adverse events. Bellicum will be working with U.S. clinical sites to resume patient recruitment based on the amended protocols.